2. De Leo V, Musacchio MC, Cappelli V, Piomboni P, Morgante G. Hormonal contraceptives: pharmacology tailored to women’s health. Hum Reprod Update. 2016; 22:634–46.
3. Kim JS, Cho S. Clinical use of oral contraceptives. J Korean Med Assoc. 2017; 60:687–93.
4. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrøm J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost. 2007; 5:692–9.
5. US Food and Drug Administration. FDA Drug Safety Communication: updated information about the risk of blood clots in women taking birth control pills containing drospirenone [Internet]. Silver Spring (MD): US Food and Drug Administration;c2012. [cited 2015 July 17]. Available from:
http://www.fda.gov/Drugs/DrugSafety/ucm299305.htm
.
6. Helmerhorst FM, Rosendaal FR. Is an EMA review on hormonal contraception and thrombosis needed? BMJ. 2013; 346:f1464.
7. Gronich N, Lavi I, Rennert G. Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based cohort study. CMAJ. 2011; 183:E1319–25.
8. Fruzzetti F, Perini D, Spirito N, Manca R. Oral contraceptive pill and thrombotic risk: epidemiological studies. Minerva Ginecol. 2012; 64:539–49.
9. Vandenbroucke JP, Rosing J, Bloemenkamp KW, Middeldorp S, Helmerhorst FM, Bouma BN, et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med. 2001; 344:1527–35.
10. Bae SH, Kim KH, Whang JY, Lee JM, Kim JM, Ku JM, et al. Treatment by transradial urokinase infusion and percutaneous transhepatic thrombectomy in superior mesenteric veno us thrombosis with intestinal infarction. Korean J Med. 2018; 93:55–60.
11. Kim JY, Kim YS. Pulmonary embolism and deep vein thrombosis related to oral contraceptive use. Obstet Gynecol Sci. 2013; 56:273–6.
12. Park MJ, Jeon GH. Pulmonary embolism in a healthy woman using the oral contraceptives containing desogestrel. Obstet Gynecol Sci. 2017; 60:232–5.
13. Yeo MS, Kwon YS, Choi SH, Kim KH, Byun CG, Koh YT, et al. SMV thrombosis on taking oral contraceptive with protein C and protein S deficiency. Ann Surg Treat Res. 2006; 71:222–5.
14. Park JH, Yang JH, Yoo DS, Cho KS, Huh PW, Kwon SO, et al. Deep cerebral venous thrombosis: successful treatment by systemic urokinase followed by heparin: case report. J Korean Neurosurg Soc. 2001; 30:99–104.
15. Cushman M, Kuller LH, Prentice R, Rodabough RJ, Psaty BM, Stafford RS, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA. 2004; 292:1573–80.
16. Lidegaard Ø, Løkkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ. 2009; 339:b2890.
17. van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ. 2009; 339:b2921.
18. Li J, Panucci G, Moeny D, Liu W, Maro JC, Toh S, et al. Association of risk for venous thromboembolism with use of low-dose extended- and continuous-cycle combined oral contraceptives: a safety study using the sentinel distributed database. JAMA Intern Med. 2018; 178:1482–8.
19. Conard J. Biological coagulation findings in third-generation oral contraceptives. Hum Reprod Update. 1999; 5:672–80.
20. Bladbjerg EM, Skouby SO, Andersen LF, Jespersen J. Effects of different progestin regimens in hormone replacement therapy on blood coagulation factor VII and tissue factor pathway inhibitor. Hum Reprod. 2002; 17:3235–41.
21. Suzuki A, Sanda N, Miyawaki Y, Fujimori Y, Yamada T, Takagi A, et al. Down-regulation of PROS1 gene expression by 17beta-estradiol via estrogen receptor alpha (ERalpha)-Sp1 interaction recruiting receptor-interacting protein 140 and the corepressor-HDAC3 complex. J Biol Chem. 2010; 285:13444–53.
22. Ali HO, Stavik B, Dørum E, Iversen N, Sandset PM, Skretting G. Oestrogen induced downregulation of TFPI expression is mediated by ERα. Thromb Res. 2014; 134:138–43.
23. Hughes Q, Watson M, Cole V, Sayer M, Baker R, Staton J. Upregulation of protein S by progestins. J Thromb Haemost. 2007; 5:2243–9.
24. Kozuka T, Tamura S, Kawamura N, Nakata Y, Hasebe R, Makiyama A, et al. Progestin isoforms provide different levels of protein S expression in HepG2 cells. Thromb Res. 2016; 145:40–5.
25. Lee SH, Lee IY, Kim EA. Experience of taking oral contraceptives in adult women. Korean J Women Health Nurs. 2017; 23:265–75.
26. Kobayashi T, Sugiura K, Ojima T. Risks of thromboembolism associated with hormone contraceptives in Japanese compared with Western women. J Obstet Gynaecol Res. 2017; 43:789–97.
27. Sugiura K, Kobayashi T, Ojima T. Risks of thromboembolism associated with hormonal contraceptives related to body mass index and aging in Japanese women. Thromb Res. 2016; 137:11–6.
28. Parkin L, Sharples K, Hernandez RK, Jick SS. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database. BMJ. 2011; 342:d2139.
29. Lidegaard Ø. Smoking and use of oral contraceptives: impact on thrombotic diseases. Am J Obstet Gynecol. 1999; 180(6 Pt 2):S357–63.
30. Roy S. Effects of smoking on prostacyclin formation and platelet aggregation in users of oral contraceptives. Am J Obstet Gynecol. 1999; 180(6 Pt 2):S364–8.
31. Lidegaard Ø, Edström B, Kreiner S. Oral contraceptives and venous thromboembolism: a five-year national case-control study. Contraception. 2002; 65:187–96.
32. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet. 1995; 346:1589–93.
33. de Bastos M, Stegeman BH, Rosendaal FR, Van Hylckama Vlieg A, Helmerhorst FM, Stijnen T, et al. Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev. 2014; (3):CD010813.
34. Hugon-Rodin J, Gompel A, Plu-Bureau G. Epidemiology of hormonal contraceptives-related venous thromboembolism. Eur J Endocrinol. 2014; 171:R221–30.
35. Bousser MG, Ferro JM. Cerebral venous thrombosis: an update. Lancet Neurol. 2007; 6:162–70.
36. Gillum LA, Mamidipudi SK, Johnston SC. Ischemic stroke risk with oral contraceptives: a meta-analysis. JAMA. 2000; 284:72–8.
37. Dentali F, Crowther M, Ageno W. Thrombophilic abnormalities, oral contraceptives, and risk of cerebral vein thrombosis: a meta-analysis. Blood. 2006; 107:2766–73.
38. Le Gal G, Kovacs MJ, Carrier M, Do K, Kahn SR, Wells PS, et al. Risk of recurrent venous thromboembolism after a first oestrogen-associated episode. Data from the REVERSE cohort study. Thromb Haemost. 2010; 104:498–503.
39. Kearon C, Spencer FA, O’Keeffe D, Parpia S, Schulman S, Baglin T, et al. D-dimer Optimal Duration Study Investigators. D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study. Ann Intern Med. 2015; 162:27–34.
40. Blanco-Molina Á, Trujillo-Santos J, Pesavento R, Rosa V, Falgá C, Tolosa C, et al. Outcome after discontinuing anticoagulant therapy in women with venous thromboembolism during hormonal use. Thromb Res. 2017; 151(Suppl 1):S6–10.